Literature DB >> 11297604

CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production.

Y Tomer1, D A Greenberg, G Barbesino, E Concepcion, T F Davies.   

Abstract

One of the hallmarks of the human autoimmune thyroid diseases (AITDs) is the production of high titers of autoantibodies against thyroglobulin and thyroid peroxidase that often precedes the development of clinical disease. A high percentage of family members of patients with AITDs have significant titers of thyroid antibodies (TAbs), suggesting a genetic predisposition for their development, and segregation analyses have favored a dominant mode of inheritance. The aim of the present study was to identify the susceptibility genes for TAb production. We completed a genome-wide scan in 56 multiplex families (323 individuals) in which all family members with AITDs and/or detectable TAbs were considered affected. The highest 2-point logarithm of odds (LOD) score of 3.6 was obtained for marker D2S325 on chromosome 2q33 at 210.9 centimorgans. This locus showed no evidence for linkage to Graves' disease or Hashimoto's thyroiditis (2-point LOD scores, 0.42 for Graves' disease and -0.60 for Hashimoto's thyroiditis), demonstrating that the gene in this region conferred susceptibility to TAbs, but that clinical disease development required additional genetic and/or environmental factors. We then fine-mapped the region linked with TAbs using 11 densely spaced microsatellite markers. Multipoint linkage analysis using these markers showed a maximum LOD score of 4.2 obtained for marker D2S155 at 209.8 centimorgans (with heterogeneity, alpha = 0.41). As the linked region contained the CTLA-4 and CD28 genes, we then tested whether they were the susceptibility genes for TAbs on chromosome 2q33. The CD28 gene was sequenced in 15 individuals, and a new C/T single nucleotide polymorphism (SNP) was identified in intron 3. Analysis of this SNP revealed no association with TAbs in the probands of the linked families (families that were linked with D2S155) compared with controls. The CTLA-4 gene was analyzed using the known A/G(49) SNP, and the results showed a significantly increased frequency of the G allele in the probands of the linked families compared with the probands of the unlinked families or with controls (P = 0.02). We concluded that 1) a major gene for thyroid autoantibody production was located on chromosome 2q33; 2) the TAb gene on chromosome 2q33 was most likely the CTLA-4 gene and not the CD28 gene; and 3) CTLA-4 contributed to the genetic susceptibility to TAb production, but there was no evidence that it contributed specifically to Graves' or Hashimoto's diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11297604     DOI: 10.1210/jcem.86.4.7372

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  35 in total

1.  Genetic profiling in Graves' disease: further evidence for lack of a distinct genetic contribution to Graves' ophthalmopathy.

Authors:  Xiaoming Yin; Rauf Latif; Rebecca Bahn; Terry F Davies
Journal:  Thyroid       Date:  2012-06-04       Impact factor: 6.568

2.  Association of CT60 cytotoxic T lymphocyte antigen-4 gene polymorphism with thyroid autoantibody production in patients with Hashimoto's and postpartum thyroiditis.

Authors:  K Zaletel; B Krhin; S Gaberscek; A Bicek; T Pajic; S Hojker
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

3.  Exon 33 T/T genotype of the thyroglobulin gene is a susceptibility gene for Graves' disease in Taiwanese and exon 12 C/C genotype protects against it.

Authors:  Jeng-Yueh Hsiao; Ming-Chia Hsieh; Kai-Jen Tien; Shih-Chie Hsu; Shiu-Ru Lin; Der-Shin Ke
Journal:  Clin Exp Med       Date:  2008-04-03       Impact factor: 3.984

4.  Employing a recombinant HLA-DR3 expression system to dissect major histocompatibility complex II-thyroglobulin peptide dynamism: a genetic, biochemical, and reverse immunological perspective.

Authors:  Eric M Jacobson; Heyi Yang; Francesca Menconi; Rong Wang; Roman Osman; Luce Skrabanek; Cheuk Wun Li; Mohammed Fadlalla; Alisha Gandhi; Vijaya Chaturvedi; Eric P Smith; Sandy Schwemberger; Andrew Osterburg; George F Babcock; Yaron Tomer
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

Review 5.  Role of genetic and non-genetic factors in the etiology of Graves' disease.

Authors:  M Marinò; F Latrofa; F Menconi; L Chiovato; P Vitti
Journal:  J Endocrinol Invest       Date:  2014-11-25       Impact factor: 4.256

6.  Common and unique susceptibility loci in Graves and Hashimoto diseases: results of whole-genome screening in a data set of 102 multiplex families.

Authors:  Yaron Tomer; Yoshiyuki Ban; Erlinda Concepcion; Giuseppe Barbesino; Ronald Villanueva; David A Greenberg; Terry F Davies
Journal:  Am J Hum Genet       Date:  2003-09-12       Impact factor: 11.025

Review 7.  Interferon alpha treatment and thyroid dysfunction.

Authors:  Yaron Tomer; Jason T Blackard; Nagako Akeno
Journal:  Endocrinol Metab Clin North Am       Date:  2007-12       Impact factor: 4.741

Review 8.  Thyrotropin receptor-associated diseases: from adenomata to Graves disease.

Authors:  Terry F Davies; Takao Ando; Reigh-Yi Lin; Yaron Tomer; Rauf Latif
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

9.  Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease.

Authors:  Yoshiyuki Ban; David A Greenberg; Erlinda Concepcion; Lucy Skrabanek; Ronald Villanueva; Yaron Tomer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

Review 10.  Interferon induced thyroiditis.

Authors:  Yaron Tomer; Francesca Menconi
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.